Considering the high prevalence of NEC-specific cell surface molecules, DLL3 could be a compelling therapeutic opportunity for an antigen targeted by antibody–drug conjugates (ADCs), bispecific T-cell engager (BiTE), and chimeric antigen receptor (CAR) T cells in GEP-NECs (Fig. 2). The gene discussed is DLL3; the disease is neuroendocrine carcinoma.